| 前收市價 | 0.2300 |
| 開市 | 0.2500 |
| 買盤 | 0.0500 |
| 賣出價 | 0.3000 |
| 拍板 | 3.00 |
| 到期日 | 2024-10-18 |
| 今日波幅 | 0.2500 - 0.2500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 369 |
ZacksPfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program is expected to save nearly $1.5 billion by 2027-end.
ZacksHere's Why Marinus Pharmaceuticals (MRNS) is Poised for a Turnaround After Losing -7.8% in 4 Weeks
Marinus Pharmaceuticals (MRNS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
ZacksAfter Plunging -7.64% in 4 Weeks, Here's Why the Trend Might Reverse for Marinus Pharmaceuticals (MRNS)
Marinus Pharmaceuticals (MRNS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
